Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Almirall reports positive data from IBS drug trial

Almirall reports positive data from IBS drug trial

2nd November 2010

Almirall has published encouraging phase III data from a clinical trial of its drug linaclotide, a new treatment for sufferers of irritable bowel syndrome (IBS).

The company has conducted a study, in association with development partner Ironwood Pharmaceuticals, which compared the efficacy and safety of the treatment to placebo among IBS patients with constipation.

It was found that linaclotide delivered statistically significant improvements in all four primary endpoints, such as reducing abdominal pain and discomfort, as well as facilitating complete spontaneous bowel movements.

Per Olof Andersson, chief scientific officer at Almirall, said: "These very positive results represent a significant milestone in the phase III clinical trial programme for linaclotide."

Almirall is Ironwood's European partner in the development of the drug, which is being supported by Forest Laboratories and Astellas Pharma in other territories.

This comes after further positive data for a once-daily 266 mcg dosing of the drug was published in September 2010.ADNFCR-8000103-ID-800210680-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.